MedPath

Feasibility Study of Normobaric Oxygen Delivered by a High Flow Concentrator in the Treatment of Chronic Headache

Not Applicable
Conditions
Chronic Headache
Interventions
Device: platinium IRC9LXO2AWQ
Registration Number
NCT02302027
Lead Sponsor
Association pour la Recherche au Centre d'Urgence des Céphalées
Brief Summary

Chronic headache is most often associated with drug abuse and medication overuse headache (MOH) is the main complication of migraine disease results in chronic daily headache. The first phase of treatment consists of drug withdrawal .

The second phase of treatment (called consolidation) is to maintain the balance: treating headaches and reducing / stopping the drug use.

The aim of this study is

1. verify the feasibility of a home withdrawal treatment with normobaric oxygen therapy (NOT) delivery by high flow concentrator

2. use normobaric oxygen therapy (NOT) as a therapeutic measure to treat headache through withdrawal period.

It is a feasibility pilot study in chronic headache with or without medication-overuse. All patients receive a care for outpatient withdrawal that involves sudden stop drug abuse and used to be called "traditional management". The subsequent attacks will be treated with NOT from a high-flow concentrator

Primary endpoint. Feasibility study of treatment with NOT evaluated by the percentage of patients who accepted NOT during the withdrawal phase then to treat attacks.

Secondary endpoints. Efficacy will be assessed by the percentage of patients having no chronic headaches two months after the start of withdrawal (less than 15 days of headache per month) and no longer in drug abuse (less than 10 days per month with drug intake).

Visits V1 (first visit) Inclusion V2 at one month V3 at 3 months V4 (last vist) at 6 months

Effective : 30 patients

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
30
Inclusion Criteria
  • Migrainous according to the criteria of the International Headache Society
  • Medication-overuse headaches according of the International Headache Society
  • No prophylaxis treatment or same prophylaxis treatment from more than one month
  • Signed informed consent
Exclusion Criteria
  • Pregnancy
  • One or more failed withdrawal treatment
  • analgesic treatment for another reason than headache
  • Contraindication of normobaric oxygen therapy
  • Contraindication of ketoprofen (rescue therapy)

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
platinium IRC9LXO2AWQplatinium IRC9LXO2AWQNormobaric oxygen therapy with high flow concentrator to treat headaches attacks, 30 minutes of oxygene inhalation with mask, 9l/minute, no frequency limitation
Primary Outcome Measures
NameTimeMethod
percentage of patients accepted the normobaric oxygen treatment during withdrawal and consolidation phases6th month
Secondary Outcome Measures
NameTimeMethod
Patient Global Impressions of Change Scale1st, 2d, 3rd, 4th, 5th and 6th month
number of headache days per month6th month
Hospital Anxiety and Depression Scale1st month, 2d month and 3rd month
Headache Impact Test- 61st, 2d and 3rd month
number of session of oxygen during the 6 months6th month
number of rescue medication taking on the 6 months6th month
Migraine Disability Assessment Questionnaire Scale3rd and 6th month

Trial Locations

Locations (1)

Centre d'Urgence des Céphalées, hôpital Lariboisière

🇫🇷

Paris, France

© Copyright 2025. All Rights Reserved by MedPath